2 reports of this reaction
1.4% of all LIDOCAINE AND MENTHOL reports
#16 most reported adverse reaction
RASH ERYTHEMATOUS is the #16 most commonly reported adverse reaction for LIDOCAINE AND MENTHOL, manufactured by Rite Aid Corporation. There are 2 FDA adverse event reports linking LIDOCAINE AND MENTHOL to RASH ERYTHEMATOUS. This represents approximately 1.4% of all 148 adverse event reports for this drug.
Patients taking LIDOCAINE AND MENTHOL who experience rash erythematous should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH ERYTHEMATOUS is a less commonly reported adverse event for LIDOCAINE AND MENTHOL, but still significant enough to appear in the safety profile.
In addition to rash erythematous, the following adverse reactions have been reported for LIDOCAINE AND MENTHOL:
The following drugs have also been linked to rash erythematous in FDA adverse event reports:
RASH ERYTHEMATOUS has been reported as an adverse event in 2 FDA reports for LIDOCAINE AND MENTHOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH ERYTHEMATOUS accounts for approximately 1.4% of all adverse event reports for LIDOCAINE AND MENTHOL, making it a notable side effect.
If you experience rash erythematous while taking LIDOCAINE AND MENTHOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.